After having scaled its own projects on the cloud, consulting firm Convergency put its technology and services on the market, aiming to support drug researchers and developments in continuing with their ongoing development projects through a cloud technology co-working space.
The technology is designed for up to globally operational pharmaceutical companies, and it enables direct internal sharing and management of clinical data within organizations.
According to the company, their customized services enable organizations to adopt new technologies rapidly, enabling them to quickly evaluate the effectiveness of drugs on COVID-19 and health issues. The accelerated data analytics process cuts typical delivery times up to 70%, while adhering to regulatory and compliance requirements, the coompany said.
The product houses data analysis capabilities, which, according to Convergency, have the potential to cut typical implementation times up to 70%. Moreover, the product integrates features for regulatory and compliance requirements adherence.
“The race to find treatments and possible cures for COVID-19 is in full force. For drug discovery, having timely and relevant data, and seamless data sharing, is a critical part of finding the solution,” said Brian Nigl, CEO of Convergency.
He added that, with millions of workers and companies relegated to home offices during the pandemic, it’s essential that data can be easily shared and made widely available, also suggesting that the software platform would remain available for future emergency situations.
“Companies must build robust, cloud-based systems to account for their workforce being remote,” concluded Nigl.